We also found that although most patients received guideline-guided heart failure therapy (ACEI/ARB, β-blockers, and Aldosterone receptor antagonist) at baseline, their proportion was lower than expected in global heart failure trials, which may reflect the gap in the actual treatment of patients with heart failure in most Asian countries. Here, NR3C2 is linked to heart failure.